tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Ascendis Pharma’s Yorvipath: A Competitive Edge in Hypoparathyroidism Treatment Drives Buy Recommendation
PremiumRatingsAscendis Pharma’s Yorvipath: A Competitive Edge in Hypoparathyroidism Treatment Drives Buy Recommendation
16d ago
Ascendis Pharma Closes Warrant Exercise Window, Boosts Share Capital
Premium
Company Announcements
Ascendis Pharma Closes Warrant Exercise Window, Boosts Share Capital
19d ago
Wedbush sees no threat to Ascendis’ Yorvipath from competitor data
Premium
The Fly
Wedbush sees no threat to Ascendis’ Yorvipath from competitor data
26d ago
Ascendis Pharma Grants Employee Warrants to Boost Engagement
PremiumCompany AnnouncementsAscendis Pharma Grants Employee Warrants to Boost Engagement
1M ago
Ascendis Pharma price target raised to $230 from $227 at BofA
Premium
The Fly
Ascendis Pharma price target raised to $230 from $227 at BofA
2M ago
Ascendis Pharma: Buy Rating Affirmed on Yorvipath Approval and TransCon CNP Prospects
Premium
Ratings
Ascendis Pharma: Buy Rating Affirmed on Yorvipath Approval and TransCon CNP Prospects
2M ago
Ascendis Pharma price target raised to $227 from $194 at TD Cowen
PremiumThe FlyAscendis Pharma price target raised to $227 from $194 at TD Cowen
2M ago
Ascendis Pharma price target raised to $230 from $210 at RBC Capital
Premium
The Fly
Ascendis Pharma price target raised to $230 from $210 at RBC Capital
2M ago
Ascendis Pharma price target raised to $307 from $306 at UBS
Premium
The Fly
Ascendis Pharma price target raised to $307 from $306 at UBS
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100